Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. Co-Diagnostics, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Industry, Sector and Symbol
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CODX
CUSIPN/A
Phone+1-801-2789769
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-149,750.40%
Return on Equity-3,935.44%
Return on Assets-479.06%
Miscellaneous
EmployeesN/A
Outstanding Shares11,920,000
Co-Diagnostics (NASDAQ:CODX) Frequently Asked Questions
What is Co-Diagnostics' stock symbol?
Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."
Who are some of Co-Diagnostics' key competitors?
Some companies that are related to Co-Diagnostics include Oncimmune (ONC), Profound Medical (PRN), Lexagene (LXG), Sernova (SVA), SQI Diagnostics (SQD), Parallax Health Sciences (PRLX), Cambridge Cognition (COG), LED Medical Diagnostics (LMD), 3D Signatures (DXD), GeneNews (GEN), Oxford Advanced Surfaces Gro (CRON), Epistem (GDR), Eternity Healthcare (ETAH), Imaging Dynamics (IDL) and Med Biogene (MBI).
Who are Co-Diagnostics' key executives?
Co-Diagnostics' management team includes the folowing people:
- Mr. Dwight H. Egan, CEO, Pres & Chairman (Age 63)
- Dr. Brent C. Satterfield Ph.D., Co-Founder, Chief Science Officer, CTO & Director (Age 41)
- Mr. Reed L. Benson Esq., CFO, Sec. & Gen. Counsel (Age 70)
When did Co-Diagnostics IPO?
(CODX) raised $9 million in an initial public offering (IPO) on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities acted as the underwriters for the IPO.
Has Co-Diagnostics been receiving favorable news coverage?
Media stories about CODX stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Co-Diagnostics earned a coverage optimism score of 0.14 on Accern's scale. They also gave news articles about the company an impact score of 46.91 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of Co-Diagnostics?
Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Co-Diagnostics' stock price today?
One share of CODX stock can currently be purchased for approximately $3.88.
How big of a company is Co-Diagnostics?
Co-Diagnostics has a market capitalization of $26.78 million.
How can I contact Co-Diagnostics?
Co-Diagnostics' mailing address is 4049 S Highland Dr, SALT LAKE CITY, UT 84124-1664, United States. The company can be reached via phone at +1-801-2789769.
MarketBeat Community Rating for Co-Diagnostics (CODX)
MarketBeat's community ratings are surveys of what our community members think about Co-Diagnostics and other stocks. Vote "Outperform" if you believe CODX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CODX will underperform the S&P 500 over the long term. You may vote once every thirty days.
